Frequently Asked Questions

Explore our most commonly asked questions regarding medical cannabis and pain management. If you want to know more, please get in touch.
Limited research has been carried out exploring the effectiveness of medical cannabis in treating various medical conditions. The studies that have been undertaken have focused mainly on the following five areas.
  • Chemotherapy-induced nausea and vomiting
  • Epilepsy
  • Multiple sclerosis
  • Chronic non-cancer pain
  • Palliative care
Visit the TGA website for the latest research into medical cannabis.
Medical cannabis is only available through the Therapeutic Goods Administration (TGA) Special Access Scheme (Cat B) or through the Authorised Prescriber scheme. Cymra Pharma cannot provide medical cannabis products directly to individuals under any circumstances.
Patients wishing to access medical cannabis products should discuss suitability with their physician and make themselves familiar with the prescribing process by reading the TGA advice at www.tga.gov.au/access-medicinal-cannabis-products. Cymra Pharma is only able to supply pharmacies with WMMC Medicinal Cannabis products once the TGA has authorised access and all approval documents have been provided to and verified by Cymra Pharma.
The TGA have put together a useful resource which summarises the requirements for an Australian registered medical practitioner to access medicinal cannabis products. Included also is information to determine state/territory regulatory requirements. See: www.tga.gov.au/access-medicinal-cannabis-products-steps-using-access-schemes.
Cymra Pharma products are TGO93 organically certified cannabis tinctures. Our world-class products go through multiple safety and standard inspections before they are delivered to patients.
If you are a physician and would like to discuss our products, testing process and analysis please request a copy of our Certificate of Analysis.
Cymra Pharma products are delivered either orally or sublingually. The route of administration will likely lead to variable effects of the product. Sublingual administration results in faster onset of effects due to its rapid entry into the blood stream and limited drug degradation by the liver before it reaches the brain. This rapid onset is beneficial when considering diseases that require rapid symptomatic relief. Oral administration results in a much slower onset of action due to the slower entry into the blood stream through the digestive system and circulation through the liver before reaching the brain. Oral administration also results in a far longer duration of action, lasting up to 12 hours in some cases. This extended duration of action is beneficial for long term symptomatic relief for patients and requires fewer doses through the day.
Pharmacokenitic and PKI studies are being conducted currently in Australia. For Canadian based guidelines for dosage please request our dosage information sheet.
Cannabis oil should be stored in a cool place out of direct sunlight. It can be kept in the fridge or freezer for long term storage, however the oil will solidify at cold temperatures and will need to be warmed before it can be used.
There are several, with many suggesting the efficacy of medical cannabis in addressing neuropathic pain. Some major work includes that of the National Academies of Science and Engineering in the USA that stated the clinical potential for medical cannabis in treating chronic pain was extremely high. Some additional examples below:
 
  1. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Berman JS, Symonds C, Birch R. 2004
  2. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Jain AK, Ryan JR, McMahon FG, Smith G. 1981
  3. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. 2003
  4. Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. Lynch ME, Clark AJ. 2003
  5. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. 2007
  6. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. 2008
  7. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Roberts JD, Gennings C, Shih M. 2006
  8. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Holdcroft A, Maze M, Dore C, Tebbs S, Thompson S. 2006
  9. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Schley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. 2006
  10. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Lynch ME, Cesar-Rittenberg P, Hohmann AG. 2014
  11. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. McCormick M, Abrams D, Alegria M, Checkley M, Collins RL, Cooper Z, Du Plessis A, Feldstein Ewing S, Hennessy S, Hutchison K, Kaminski N, Patel S, Piomelli D, Sidney S, Wallace R, Williams J. 2017
Cymra Pharma is undertaking a clinical trial with Newcastle University. We are interested in partnering with other research organisations. Please contact us to discuss further partnerships.
There are also several other clinical trials occurring in Australia at present. It will be some time before completion and evidence collection.